Skip to main content
logo
Lyell Immunopharma logo
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
8.19
+0.20 (2.50%)
Oct 15, 2026, 4:00 PM EDT - Market closed

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
2016541874898651,861
Market Cap Growth
-37.93%249.70%-61.73%-43.52%-53.52%-
Enterprise Value
19387-215-45182992
Last Close Price
8.1930.7812.8038.8069.40154.80

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
7433.2318163.583065.303758.6610.22174.77
PB Ratio
0.822.640.490.751.042.00
P/TBV Ratio
0.862.640.490.751.042.00

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
714.7110759.39--2.1593.15

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.200.210.150.100.080.07
Net Debt / Equity Ratio
-0.78-0.79-0.85-0.76-0.77-0.89
Net Debt / EBITDA Ratio
1.001.051.632.223.804.15
Net Debt / FCF Ratio
1.351.301.993.003.324.33
Asset Turnover
00000.080.01
Quick Ratio
5.125.006.8915.8217.2913.15
Current Ratio
5.365.287.0616.0717.5913.40
Return on Equity (ROE)
-93.28%-86.98%-66.10%-31.53%-20.77%-30.36%
Return on Assets (ROA)
-34.18%-29.83%-22.05%-18.18%-11.32%-13.11%
Return on Capital Employed (ROCE)
-70.20%-68.20%-50.10%-34.30%-20.80%-19.80%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-123.81%-41.97%-183.44%-48.02%-21.17%-13.44%
FCF Yield
-66.75%-23.06%-87.10%-34.05%-22.40%-10.30%
Buyback Yield / Dilution
-49.16%-30.74%-4.18%-1.58%-81.79%-925.18%
SEC Filings: 10-K · 10-Q